These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30227506)

  • 1. Analysis of Medical Information Responses to Unsolicited Health Care Worker Inquiries Submitted via Sales Representatives or Customers Directly.
    Fuentes RJ; Kim R; Idowu K; Susla G
    Ther Innov Regul Sci; 2014 Mar; 48(2):155-161. PubMed ID: 30227506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responding to Unsolicited Medical Requests from Health Care Professionals on Pharmaceutical Industry-Owned Social Media Sites: Three Pilot Studies.
    TenBarge AM; Riggins JL
    J Med Internet Res; 2018 Oct; 20(10):e285. PubMed ID: 30373730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
    Larkin I; Ang D; Avorn J; Kesselheim AS
    Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Literature for Oncology Data Gaps to Improve the Quality of Standard Response Letters: A Retrospective Review.
    Monestime S
    Ther Innov Regul Sci; 2020 Mar; 54(2):385-389. PubMed ID: 32072589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
    Gentry G
    Food Drug Law J; 2009; 64(3):441-58. PubMed ID: 19999637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of face-to-face educational outreach on diarrhoea treatment in pharmacies.
    Ross-Degnan D; Soumerai SB; Goel PK; Bates J; Makhulo J; Dondi N; Sutoto ; Adi D; Ferraz-Tabor L; Hogan R
    Health Policy Plan; 1996 Sep; 11(3):308-18. PubMed ID: 10160376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encounters with pharmaceutical sales representatives among practicing internists.
    Ferguson RP; Rhim E; Belizaire W; Egede L; Carter K; Lansdale T
    Am J Med; 1999 Aug; 107(2):149-52. PubMed ID: 10460046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance Within Medical Information and the Emergence of a Medical Information-Dedicated Compliance Person: A Benchmarking Survey.
    Chen L; Scheld H
    Ther Innov Regul Sci; 2014 Jul; 48(4):494-497. PubMed ID: 30235565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. phactMI™ Benchmarking Survey: Analysis of 27 Medical Information Departments Responses to Inquiries from Health Care Decision Makers.
    D'Ascoli A; Gazo A; Yueh S; Egri F; Akanda S
    Ther Innov Regul Sci; 2020 Nov; 54(6):1291-1295. PubMed ID: 33140259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed Best Practice Guidelines for Scientific Response Documents: A Consensus Statement from phactMI.
    Hermes-DeSantis ER; Johnson RM; Redlich A; Patel B; Flanigan-Minnick A; Wnorowski S; Cortes MM; Han CW; Vine E; Sarwar H; Haydar R; Jamil A; Huang T; Sandhu SK; Reilly P
    Ther Innov Regul Sci; 2020 Nov; 54(6):1303-1311. PubMed ID: 33258092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Practical application of the charter of pharmaceutical sales visit].
    Leroy B; Uhart M; Lajoinie A; Maire P; Ducher M; Bourguignon L
    Ann Pharm Fr; 2012 Nov; 70(6):348-52. PubMed ID: 23177561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.
    Fickweiler F; Fickweiler W; Urbach E
    BMJ Open; 2017 Sep; 7(9):e016408. PubMed ID: 28963287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rooting out institutional corruption to manage inappropriate off-label drug use.
    Rodwin MA
    J Law Med Ethics; 2013; 41(3):654-64. PubMed ID: 24088156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What information do physicians receive from pharmaceutical representatives?
    Lexchin J
    Can Fam Physician; 1997 May; 43():941-5. PubMed ID: 9154366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requests for medical advice from patients and families to health care providers who publish on the World Wide Web.
    Widman LE; Tong DA
    Arch Intern Med; 1997 Jan; 157(2):209-12. PubMed ID: 9009978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of information on the off-label (unapproved) use of medication: a comparative analysis.
    Jansen RM
    Med Law; 2011 Mar; 30(1):115-32. PubMed ID: 21528801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chlorpyrifos: a ten-year US poison center exposure experience.
    Kingston RL; Chen WL; Borron SW; Sioris LJ; Harris CR; Engebretsen KM
    Vet Hum Toxicol; 1999 Apr; 41(2):87-92. PubMed ID: 10192137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.